The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis
Survival rates for children and adult patients with T-cell acute lymphoblastic leukemia (T-ALL) have improved during the past decade due to optimization of frontline multiagent chemotherapy regimens. The outcome for relapsed T-ALL after initial intensive chemotherapy is frequently fatal, however, be...
Saved in:
Published in | Seminars in hematology Vol. 57; no. 3; p. 149 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
01.07.2020
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Survival rates for children and adult patients with T-cell acute lymphoblastic leukemia (T-ALL) have improved during the past decade due to optimization of frontline multiagent chemotherapy regimens. The outcome for relapsed T-ALL after initial intensive chemotherapy is frequently fatal, however, because no effective salvage regimens have been developed. Immunotherapy and small molecule inhibitors are beginning to be tested in T-ALL and have the potential to advance the treatment, especially the frontline regimen by eradicating minimal residual disease thus inducing more durable remissions. In this paper, I review the current chemotherapy regimens for adult patients with T-ALL and summarize the novel immunotherapies and small molecule inhibitors that are currently in early phase clinical trials. |
---|---|
ISSN: | 1532-8686 |
DOI: | 10.1053/j.seminhematol.2020.11.004 |